Neuroblastoma

Neuroblastoma is a malignant tumor that arises from immature nerve cells called neuroblasts. It is most often diagnosed in children, particularly newborns and infants in their first year of life. The disease can develop anywhere in the body, but the most common localizations are the adrenal glands, cervical and thoracic regions, and the spine. Neuroblastoma is characterized by an aggressive course and the ability to metastasize, up to the bones, liver, and lymph nodes. Despite this, treatment in some cases leads to a complete recovery, especially if the disease was diagnosed in the early stages.

History of the disease and interesting historical facts

Neuroblastoma was first described in 1910 by German pathologist Wilhelm Letzer and has since been studied by many researchers and doctors. In 1924, its clinical course and therapy were described by the famous oncologist K. Osthoff, which helped in the formation of the early concept of the disease. An interesting fact is that neuroblastoma was long considered a rare disease in children, but in recent decades the number of cases has increased significantly, which is associated with improved diagnostic methods and more careful attention to symptoms in childhood.

Epidemiology

Neuroblastoma is statistically one of the most common solid tumors in children. In the United States, the incidence is approximately 7 cases per 1 million children under 15 years of age. The main peak incidence occurs before the age of 5, with up to 90% cases diagnosed in children under 5 years of age. Neuroblastoma generally occurs more often in boys than in girls. Regions with higher incidence include Western Europe and the United States, while low-income countries have a significantly lower incidence.

Genetic predisposition to this disease

Studies of genetic factors associated with neuroblastoma have shown that certain mutations may be associated with an increased risk of developing the tumor. In particular, genes such as ALK, MYCN, and PHOX2B are involved. Mutations in the ALK gene cause abnormal signaling pathways that promote neoplastic cell development. Children with MYCN gene amplification have a worse prognosis due to the aggressive nature of the tumor. In addition, genetic syndromes such as Down syndrome also increase the likelihood of developing neuroblastoma.

Risk factors for the development of this disease

There are various factors that can increase the risk of developing neuroblastoma, including:

• Genetic predispositions associated with certain mutations.
• Exposure to chemicals such as pesticides and formaldehyde in early childhood.
• Environmental factors including air pollution and radiation.
• Having parents with cancer or other diseases, which may indicate hereditary tendencies.
• Immune disorders that may contribute to the development of tumors.

Diagnosis of this disease

Diagnosis of neuroblastoma includes a number of stages and methods, including:

• The main symptoms are swelling, abdominal pain, sudden enlargement of the lymph nodes, anemia, fatigue and irritability in the child.
• Lab tests: Blood tests for chemicals associated with neuroblastoma, such as metanephrines and vanillylmandelic acid.
• Radiological examinations: ultrasound, CT, MRI and PET to localize the tumor and detect metastases.
• Histological examinations: biopsy to confirm the diagnosis and determine the characteristics of the tumor.
• Differential diagnosis: exclusion of other tumors and diseases such as mediastinal tumors and lymphomas.

Treatment

Treatment for neuroblastoma may involve a variety of methods:

• General therapy: a combination approach including surgery, chemotherapy and radiotherapy.
• Pharmacological treatment: use of cytostatics and new immunotherapeutic agents.
• Surgical intervention: removal of the tumor and, if necessary, lymph nodes.
• Other treatments include targeted therapy and stem cell transplantation in children with recurrent disease.

List of medications used to treat this disease

The following groups of drugs are used to treat neuroblastoma:

• Cytostatics: platinum (cisplatin), vincristine, cyclophosphamide.
• Immunotherapeutic agents: dinutuzumab vedotin, interferons.
• Targeted drugs: ALK inhibitors such as crizotinib.
• Supportive care: anemia and bone marrow support.

Disease monitoring

Monitoring of neuroblastoma includes regular examinations and checkpoints, such as:

• Evaluation of markers in blood and urine to determine disease activity.
• Radiological examinations to detect possible recurrence or metastases.
• Clinical examinations to detect changes in the patient's condition.
• Prognosis: Depending on the stage at diagnosis and the characteristics of the tumor, survival varies from 30% to 80%.
• Complications include high doses of chemotherapy, which can lead to long-term effects including cardiovascular and reproductive problems.

Age-related features of the disease

Neuroblastoma can manifest itself differently depending on the patient's age. In newborns, it often has a favorable course and may even regress on its own, while in older children, a more aggressive course is observed. In children under 3 years of age, localized forms with a good prognosis are more common, while in children over 5 years of age, more aggressive forms with a high risk of metastases are observed.

Questions and Answers

• What is neuroblastoma? Neuroblastoma is a malignant tumor that arises from immature nerve cells and is common in children, especially infants.
• What are the main symptoms of neuroblastoma? The main symptoms include abdominal distension, pain, anemia, fatigue and irritability in the child.
• How is neuroblastoma diagnosed? Diagnosis includes blood tests, markers, radiological studies and biopsy to confirm the diagnosis.
• How is neuroblastoma treated? Treatment includes chemotherapy, surgery and immunotherapy depending on the stage of the disease.
• What is the prognosis for neuroblastoma? The prognosis depends on the stage of the disease and can vary from 30% to 80% survival depending on the tumor type and the patient's age.